Furthermore, a recent sub-analysis on anticoagulated patients with AF and diabetes enrolled in the randomized Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, highlighted a heightened cardiovascular risk, mainly related to the occurrence of myocardial infarction (MI) and cardiovascular death, largely confined to diabetes requiring insulin [8]. The gene discussed is INS; the disease is Stroke.